News Sentiment

ALNY sentiment intelligence

Alnylam Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 267.47 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.5% over one week, -3.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

US2043QAC1 Bond Profile — Key Metrics

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -10.5% Price reacting lower
Trend fit Trend inactive -3.8% over four weeks
Fair value -1.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 33
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Investing.com 5
simplywall.st 5
Simply Wall Street 4
Moomoo 4
TradingView 3
ChartMill 3
Quartr 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 19
Analyst action 11
Guidance 3
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
TradingView Direct company coverage

US2043QAC1 Bond Profile — Key Metrics

This article provides key metrics for the Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028 US2043QAC1 bond, traded on the Frankfurt Stock Exchange.

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2026 05:40
Source
TradingView
Quartr Direct company coverage

Alnylam Pharmaceuticals (ALNY) Q2 2024 earnings summary

Alnylam Pharmaceuticals (ALNY) reported strong Q2 2024 results, with net product revenues up 34% year-over-year to $410.1M and total revenues reaching $660M, a 107% increase. The company raised its 2024 net product revenue guidance to $1,575M–$1,650M following positive Phase 3 st

Tone
Positive 94/100
Event
Earnings
Published
21 Jul 2026 12:11
Source
Quartr
Simply Wall Street Direct company coverage

Alnylam Stock And 2 US Health Care Names With Earnings In Focus

This article examines Alnylam Pharmaceuticals (ALNY), Insulet (PODD), and Neurocrine Biosciences (NBIX), three U.S. large-cap health care stocks. It discusses their market positioning, financial outlook, and the balance of opportunities and risks they face amidst current market c

Tone
Neutral 50/100
Event
Earnings
Published
20 Jul 2026 20:09
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story?

Alnylam Pharmaceuticals (ALNY) recently presented positive Phase 1 and 2 updates for its RNAi candidate mivelsiran, targeting early-onset and Down syndrome-associated Alzheimer’s disease, at AAIC 2026. The company reported long-term biomarker reductions and a favorable safety pro

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 10:39
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com

Alnylam Pharmaceuticals (ALNY) stock has fallen to a 52-week low of $273.03, reflecting a 28.79% year-to-date and nearly 13% annual decline amidst biotechnology sector challenges. Despite the downturn, analysts maintain a bullish outlook with price targets up to $550, citing sign

Tone
Neutral 50/100
Event
Guidance
Published
18 Jul 2026 14:11
Source
Investing.com Nigeria
Simply Wall Street Direct company coverage

Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses

Alnylam Pharmaceuticals (ALNY) recently initiated a Phase 2 trial for mivelsiran in Down syndrome-associated Alzheimer’s, yet its stock price has declined by over 10% in the past week. Despite recent drops, the company is considered undervalued by analysts, trading at $267.47 aga

Tone
Positive 72/100
Event
Market update
Published
18 Jul 2026 03:11
Source
Simply Wall Street
Quartr Direct company coverage

Alnylam Pharmaceuticals (ALNY) Proxy filing Summary

Alnylam Pharmaceuticals is holding its annual virtual meeting on May 20, 2026, where shareholders will vote on the election of three Class I directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026. The company reac

Tone
Positive 77/100
Event
Market update
Published
18 Jul 2026 02:39
Source
Quartr
Investing.com Direct company coverage

Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD

Alnylam Pharmaceuticals (ALNY) stock has fallen to a 52-week low of $273.03, reflecting a nearly 29% year-to-date and 13% year-over-year decline due to biotechnology sector challenges. Despite this downturn, analysts maintain a bullish outlook with price targets up to $550, with

Tone
Negative 39/100
Event
Guidance
Published
17 Jul 2026 16:40
Source
Investing.com
Stock Traders Daily Direct company coverage

Liquidity Mapping Around (ALNY) Price Events

This article provides a quantitative analysis of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) focusing on liquidity mapping around price events. It highlights near-term weak sentiment, a significant risk-reward setup targeting a 17.9% gain versus 0.3% risk, and outlines three dist

Tone
Neutral 50/100
Event
Balance sheet
Published
17 Jul 2026 02:40
Source
Stock Traders Daily
BioSpace Direct company coverage

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. announced it will report its Q2 2026 financial results on Thursday, July 30, 2026, before the U.S. markets open. Management will discuss these results and future expectations during a conference call and live audio webcast on the same day at 8:30 am

Tone
Neutral 50/100
Event
Earnings
Published
17 Jul 2026 01:40
Source
BioSpace
Trefis Direct company coverage

Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak

Alnylam Pharmaceuticals (NASDAQ: ALNY) stock has experienced a significant downturn, dropping 14% and marking a five-day losing streak. This indicates a challenging period for the company's market performance.

Tone
Negative 19/100
Event
Market update
Published
16 Jul 2026 12:42
Source
Trefis
Trefis Direct company coverage

Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14%

Alnylam Pharmaceuticals (ALNY) stock has experienced a significant downturn, falling 14% over five consecutive trading days, erasing $5.9 billion from its market value. Despite the biotech firm's impressive 82.6% revenue growth over the last year, its high price-to-earnings multi

Tone
Negative 29/100
Event
Earnings
Published
16 Jul 2026 12:10
Source
Trefis
BioSpace Direct company coverage

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Alnylam Pharmaceuticals is advancing its neuroscience pipeline, highlighted at AAIC 2026, with RNAi therapeutics for neurological diseases. Key developments include the initiation of a Phase 2 study for mivelsiran in Down Syndrome-Associated Alzheimer’s Disease and the completion

Tone
Positive 75/100
Event
Market update
Published
15 Jul 2026 14:43
Source
BioSpace
Moomoo Direct company coverage

BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating

BofA Securities has adjusted its price target for Alnylam Pharmaceuticals (ALNY) to $410, down from its previous target of $460, while reaffirming a Buy rating on the stock. This revision reflects an updated financial outlook for the company, indicating a moderated but still posi

Tone
Positive 63/100
Event
Analyst action
Published
14 Jul 2026 15:09
Source
Moomoo
GuruFocus Direct company coverage

ALNY Maintained by B of A Securities -- Price Target Lowered to $410

B of A Securities has maintained a 'Buy' rating for Alnylam Pharmaceuticals (ALNY) but lowered its price target from $460 to $410, a 10.87% decrease. Despite this, GuruFocus indicates ALNY is currently undervalued by 46.4%, with a GF Value™ of $522.41 against a current price of $

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 15:09
Source
GuruFocus
Investing.com Direct company coverage

BofA cuts Alnylam stock price target on conservative outlook

BofA Securities has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $460 to $410, while maintaining a Buy rating. This adjustment comes despite BofA's projections for Alnylam's second-quarter revenue exceeding consensus estimates for its key drugs. The fir

Tone
Negative 35/100
Event
Analyst action
Published
14 Jul 2026 10:41
Source
Investing.com
Investing.com Direct company coverage

Truist cuts Alnylam stock price target to $410 on ATTR outlook

Truist Securities has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) to $410 from $505, maintaining a Buy rating. This adjustment comes amidst increased uncertainty for the ATTR franchise's long-term growth outlook following a failed study by competitors, whic

Tone
Negative 39/100
Event
Analyst action
Published
13 Jul 2026 13:39
Source
Investing.com